Systematic review and meta-analysis of tacrolimus versus ciclosporin as primary immunosuppression after liver transplant

PLoS ONE

Volumn 11, Issue 11, 2016, Pages

  Muduma, Gorden ^a   Saunders, Rhodri ^b   Odeyemi, Isaac ^a   Pollock, Richard F ^b  

^a Astellas Pharma Europe Ltd   (United Kingdom)

^b Ossian Health Economics and Communications GmbH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; TACROLIMUS; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRAFT REJECTION; DRUG EFFECT; GRAFT FAILURE; GRAFT RECIPIENT; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; LIVER GRAFT; LIVER GRAFT REJECTION; META ANALYSIS; MORTALITY; NEW ONSET DIABETES AFTER TRANSPLANTATION; POSTOPERATIVE COMPLICATION; REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; COMPARATIVE STUDY; LIVER TRANSPLANTATION; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC);

CYCLOSPORINE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TACROLIMUS;

EID: 84994045419     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0160421     Document Type: Review

References (53)

1. Starzl TE, Iwatsuki S, Shaw BW Jr, Gordon RD, Esquivel CO. Immunosuppression and other nonsurgical factors in the improved results of liver transplantation. Semin Liver Dis. 1985;5(4):334-43. doi: 10.1055/s-2008-1040630 PMID: 3909427
2. European FK506 Multicentre Liver Study Group. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. Lancet 1994;344:423-428. PMID: 7520105
3. The US Multicentre FK506 Study Group. A comparison of tacrolimus (FK 506) and ciclosporin for immunosuppression in liver transplantation. N Engl J Med 1994;331:1110-1115. doi: 10.1056/NEJM199410273311702 PMID: 7523946
4. Otto MG, Mayer AD, Clavien PA, Cavallari A, Gunawardena KA, Mueller EA. Randomized trial of ciclosporin microemulsion (neoral) versus conventional ciclosporin in liver transplantation: MILTON study. Multicentre International Study in Liver Transplantation of Neoral. Transplantation. 1998;66(12):1632-40. PMID: 9884251
5. Loinaz C, Marin LM, González-Pinto I, Gómez R, Jiménez C, Moreno E. A single-centre experience with ciclosporin microemulsion versus tacrolimus in 100 randomized liver transplant recipients: midterm efficacy and safety. Transplant Proc. 2001;33(7-8):3439-41. PMID: 11750472
6. Rostaing L, Saliba F, Calmus Y, Dharancy S, Boillot O. Review article: use of induction therapy in liver transplantation. Transplant Rev (Orlando). 2012;26(4):246-60.
7. Wiesner RH, Fung JJ. Present state of immunosuppressive therapy in liver transplant recipients. Liver Transpl. 2011;17 Suppl 3:S1-9. doi: 10.1002/lt.22410 PMID: 21850697
8. Fink MA, Angus PW, Gow PJ, Berry SR, Wang BZ, Muralidharan V, et al. Liver transplant recipient selection: MELD vs. clinical judgment. Liver Transpl. 2005;11(6):621-6. doi: 10.1002/lt.20428 PMID: 15915491
9. Akkina SK, Asrani SK, Peng Y, Stock P, Kim WR, Israni AK. Development of organ-specific donor risk indices. Liver Transpl. 2012;18(4):395-404. doi: 10.1002/lt.23398 PMID: 22287036
10. Reich DJ, Clavien PA, Hodge EE; MMF Renal Dysfunction after Liver Transplantation Working Group. Mycophenolate mofetil for renal dysfunction in liver transplant recipients on cyclosporine or tacrolimus: randomized, prospective, multicenter pilot study results. Transplantation. 2005;80(1):18-25. PMID: 16003228
11. McKenna GJ, Trotter JF. Sirolimus conversion for renal dysfunction in liver transplant recipients: the devil really is in the details... Am J Transplant. 2012;12(3):521-2. doi: 10.1111/j.1600-6143.2011. 03922.x PMID: 22300457
12. Busuttil RW, Holt CD. Tacrolimus is superior to ciclosporin in liver transplantation. Transplant Proc. 1998;30(5):2174-8. PMID: 9723432
13. Haddad EM, McAlister VC, Renouf E, Malthaner R, Kjaer MS, Gluud LL. Cyclosporin versus tacrolimus for liver transplanted patients. Cochrane Database Syst Rev. 2006; (4:): CD005161. doi: 10.1002/14651858. CD005161.pub2 PMID: 17054241
14. Liu Z, Chen Y, Tao R, Xv J, Meng J, Yong X. Tacrolimus-based versus ciclosporin-based immunosuppression in hepatitis C virus-infected patients after liver transplantation: a meta-analysis and systematic review. PLoS One. 2014;9(9):e107057. doi: 10.1371/journal.pone.0107057 PMID: 25198195
15. Gehr BT, Weiss C, Porzsolt F. The fading of reported effectiveness. A meta-analysis of randomised controlled trials. BMC Med Res Methodol. 2006;6:25. doi: 10.1186/1471-2288-6-25 PMID: 16689990
16. Ioannidis JP. Why most discovered true associations are inflated. Epidemiology. 2008;19(5):640-8. doi: 10.1097/EDE.0b013e31818131e7 PMID: 18633328
17. Ioannidis JP. Contradicted and initially stronger effects in highly cited clinical research. JAMA. 2005;294:218-228. doi: 10.1001/jama.294.2.218 PMID: 16014596
18. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. doi: 10.1136/bmj. d5928 PMID: 22008217
19. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177-88. PMID: 3802833
20. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22(4):719-48. PMID: 13655060
21. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557-560. doi: 10.1136/bmj.327.7414.557 PMID: 12958120
22. Cholongitas E, Burroughs AK. The evolution in the prioritization for liver transplantation. Ann Gastroenterol. 2012;25(1):6-13. PMID: 24713804
23. Trunečka P, Boillot O, Seehofer D, Pinna AD, Fischer L, Ericzon BG, et al.; Tacrolimus Prolonged Release Liver Study Group. Once-daily prolonged-release tacrolimus (ADVAGRAF) versus twicedaily tacrolimus (PROGRAF) in liver transplantation. Am J Transplant. 2010;10(10):2313-23. doi: 10. 1111/j.1600-6143.2010.03255.x PMID: 20840481
24. O'Grady JG, Burroughs A, Hardy P, Elbourne D, Truesdale A; UK and Republic of Ireland Liver Transplant Study Group. Tacrolimus versus microemulsified ciclosporin in liver transplantation: the TMC randomised controlled trial. Lancet. 2002;360(9340):1119-25. PMID: 12387959
25. Levy G, Villamil FG, Nevens F, Metselaar HJ, Clavien PA, Klintmalm G, et al.; REFINE Study Group. REFINE: a randomized trial comparing ciclosporin A and tacrolimus on fibrosis after liver transplantation for hepatitis C. Am J Transplant. 2014;14(3):635-46. doi: 10.1111/ajt.12620 PMID: 24456049
26. Glanemann M, Klupp J, Langrehr JM, Schröer G, Platz KP, Stange B, et al. Higher immunosuppressive efficacy of mycophenolate mofetil in combination with FK 506 than in combination with ciclosporin A. Transplant Proc. 2000;32(3):522-3. PMID: 10812095
27. Greig P, Lilly L, Scudamore C, Erb S, Yoshida E, Kneteman N, et al. Early steroid withdrawal after liver transplantation: the Canadian tacrolimus versus microemulsion cyclosporin A trial: 1-year follow-up. Liver Transpl. 2003;9(6):587-95. doi: 10.1053/jlts.2003.50102 PMID: 12783400
28. Fisher RA, Stone JJ, Wolfe LG, Rodgers CM, Anderson ML, Sterling RK, et al. Four-year follow-up of a prospective randomized trial of mycophenolate mofetil with ciclosporin microemulsion or tacrolimus following liver transplantation. Clin Transplant. 2004;18(4):463-72. doi: 10.1111/j.1399-0012.2004. 00192.x PMID: 15233827
29. Martin P, Busuttil RW, Goldstein RM, Crippin JS, Klintmalm GB, Fitzsimmons WE, et al. Impact of tacrolimus versus ciclosporin in hepatitis C virus-infected liver transplant recipients on recurrent hepatitis: a prospective, randomized trial. Liver Transpl. 2004;10(10):1258-62. doi: 10.1002/lt.20222 PMID: 15376310
30. González-Pinto IM, Rimola A, Margarit C, Cuervas-Mons V, Abradelo M, Alvarez-Laso C, et al. Fiveyear follow-up of a trial comparing Tacrolimus and ciclosporin microemulsion in liver transplantation. Transplant Proc. 2005;37(4):1713-5. doi: 10.1016/j.transproceed.2005.03.128 PMID: 15919441
31. Berenguer M, Aguilera V, Prieto M, San Juan F, Rayón JM, Benlloch S, et al. Effect of calcineurin inhibitors on survival and histologic disease severity in HCV-infected liver transplant recipients. Liver Transpl. 2006;12(5):762-7. doi: 10.1002/lt.20655 PMID: 16528713
32. Levy G, Grazi GL, Sanjuan F, Wu Y, Mühlbacher F, Samuel D, et al. 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing ciclosporin microemulsion (C2 monitoring) and tacrolimus. Liver Transpl. 2006;12(10):1464-72. doi: 10.1002/lt.20802 PMID: 17004259
33. Shenoy S, Hardinger KL, Crippin J, Korenblat K, Lisker-Melman M, Lowell JA, et al. A randomized, prospective, pharmacoeconomic trial of neoral 2-hour postdose concentration monitoring versus tacrolimus trough concentration monitoring in de novo liver transplant recipients. Liver Transpl. 2008;14(2):173-80. doi: 10.1002/lt.21355 PMID: 18236391
34. Cholongitas E, Shusang V, Germani G, Tsochatzis E, Raimondo ML, Marelli L, et al. Long-term followup of immunosuppressive monotherapy in liver transplantation: tacrolimus and microemulsified cyclosporin. Clin Transplant. 2011;25(4):614-24. doi: 10.1111/j.1399-0012.2010.01321.x PMID: 20718824
35. Villamil F, Levy G, Grazi GL, Mies S, Samuel D, Sanjuan F, et al. Long-term outcomes in liver transplant patients with hepatic C infection receiving tacrolimus or ciclosporin. Transplant Proc. 2006;38(9):2964-7. doi: 10.1016/j.transproceed.2006.08.131 PMID: 17112875
36. Watashi K, Ishii N, Hijikata M, Inoue D, Murata T, Miyanari Y, et al. Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase. Mol Cell. 2005;19(1):111-22. doi: 10.1016/j.molcel.2005.05. 014 PMID: 15989969
37. Irish WD, Arcona S, Bowers D, Trotter JF. Cyclosporine versus tacrolimus treated liver transplant recipients with chronic hepatitis C: outcomes analysis of the UNOS/OPTN database. Am J Transplant. 2011;11(8):1676-85. doi: 10.1111/j.1600-6143.2011.03508.x PMID: 21564522
38. Wiesner RH. A long-term comparison of tacrolimus (FK506) versus ciclosporin in liver transplantation: A report of the United States FK506 Study Group. Transplantation 1998;66:493-499. PMID: 9734494
39. Saliba F, Lakehal M, Pageaux GP, Roche B, Vanlemmens C, Duvoux C, et al.; Diapason Study Group. Risk factors for new-onset diabetes mellitus following liver transplantation and impact of hepatitis C infection: an observational multicenter study. Liver Transpl. 2007;13(1):136-44. doi: 10.1002/lt.21010 PMID: 17192854
40. Penninga L, Møller CH, Gustafsson F, Steinbrüchel DA, Gluud C. Tacrolimus versus ciclosporin as primary immunosuppression after heart transplantation: systematic review with meta-analyses and trial sequential analyses of randomised trials. Eur J Clin Pharmacol. 2010;66(12):1177-87. doi: 10.1007/s00228-010-0902-6 PMID: 20882273
41. Tam VC, Hotte SJ. Consistency of phase III clinical trial abstracts presented at an annual meeting of the American Society of Clinical Oncology compared with their subsequent full-text publications. J Clin Oncol. 2008;26(13):2205-11. doi: 10.1200/JCO.2007.14.6795 PMID: 18445846
42. Hopewell S, Clarke M, Askie L. Reporting of trials presented in conference abstracts needs to be improved. J Clin Epidemiol. 2006;59(7):681-4. doi: 10.1016/j.jclinepi.2005.09.016 PMID: 16765270
43. Toma M, McAlister FA, Bialy L, Adams D, Vandermeer B, Armstrong PW. Transition from meeting abstract to full-length journal article for randomized controlled trials. JAMA. 2006;295(11):1281-7. doi: 10.1001/jama.295.11.1281 PMID: 16537738
44. Timmermann W, Erhard J, Lange R, Reck T, Köckerling F, Müller A, et al. A randomised trial comparing the efficacy and safety of tacrolimus with microemulsified cyclosporine after liver transplantation. Transplant Proc. 2002;34(5):1516-8. PMID: 12176463
45. Therapondos G, Flapan AD, Dollinger MM, Garden OJ, Plevris JN, Hayes PC. Cardiac function after orthotopic liver transplantation and the effects of immunosuppression: a prospective randomized trial comparing cyclosporin (Neoral) and tacrolimus. Liver Transpl. 2002;8(8):690-700. doi: 10.1053/jlts. 2002.34381 PMID: 12149762
46. Mühlbacher F; European Liver Transplantation Tacrolimus vs Cyclosporin Microemulsion Study Group. Tacrolimus versus cyclosporin microemulsion in liver transplantation: results of a 3-month study. Transplant Proc. 2001;33(1-2):1339-40. PMID: 11267317
47. Adam R, Karam V, Delvart V, Trunečka P, Samuel D, Bechstein WO, et al. Improved Survival in Liver Transplant Recipients Receiving Prolonged-Release Tacrolimus in the European Liver Transplant Registry. Am J Transplant. 2015;15(5):1267-1282. doi: 10.1111/ajt.13171 PMID: 25703527
48. Eberlin M, Otto G, Krämer I. Increased medication compliance of liver transplant patients switched from a twice-daily to a once-daily tacrolimus-based immunosuppressive regimen. Transplant Proc. 2013;45(6):2314-20. doi: 10.1016/j.transproceed.2012.10.037 PMID: 23726723
49. Kuypers DR, Peeters PC, Sennesael JJ, Kianda MN, Vrijens B, Kristanto P, et al.; ADMIRAD Study Team. Improved adherence to tacrolimus once-daily formulation in renal recipients: a randomized controlled trial using electronic monitoring. Transplantation. 2013;95(2):333-40. doi: 10.1097/TP. 0b013e3182725532 PMID: 23263559
50. Florman S, Alloway R, Kalayoglu M, Lake K, Bak T, Klein A, et al. Conversion of Stable Liver Transplant Recipients From a Twice-Daily Prograf-Based Regimen to a Once-Daily Modified Release Tacrolimus-Based Regimen. Transplant Proc. 2005;37:1211-3. doi: 10.1016/j.transproceed.2004.11.086 PMID: 15848672
51. Van Onzenoort HA, Menger FE, Neef C, Verberk WJ, Kroon AA, De Leeuw PW, et al. Participation in a clinical trial enhances adherence and persistence to treatment: a retrospective cohort study. Hypertension. 2011;58(4):573-8. doi: 10.1161/HYPERTENSIONAHA.111.171074 PMID: 21825228
52. Garrison LP Jr, Neumann PJ, Erickson P, Marshall D, Mullins CD. Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report. Value Health. 2007;10(5):326-35. doi: 10.1111/j.1524-4733.2007.00186.x PMID: 17888097
53. McCarron CE, Pullenayegum EM, Thabane L, Goeree R, Tarride JE. The importance of adjusting for potential confounders in Bayesian hierarchical models synthesising evidence from randomised and non-randomised studies: an application comparing treatments for abdominal aortic aneurysms. BMC Med Res Methodol. 2010;10:64-72. doi: 10.1186/1471-2288-10-64 PMID: 20618973